Hi BDAZ.

This re-post of June 2013 compared to the current description of RVX truly highlights the tremendous progress made by these companies in understanding their molecules, scaffolds, MOA etc. Back in 2013 they spoke of rvx-208 being an Apoa-l focused and now it is MACE, inflammation, DM, Alzhemiers, orphan trial, etc.

I appreciate your explanation of the current re-org from a science POV. This is the most critical component IMHO.

I also appreciate other posters and fouremm explaining the business and share structure aspects and I really don't clearly understand what is happening. I get it broad strokes and the motivation.

Back before the original spinco in 2013 I held quite a few thousand RVX shares and so for each RVX share I was given one "common" share of Zenith.

I haven't gone back through the SEDAR filings but I seem to recall at some point that Eastern and NGN provided one or more financings to Zenith and for some reason I thought they were given preferred shares?

So what I am trying to understand is do I or anyone in my position with common shares have any preferred shares or are they for Eastern and NGN and perhapps management?

And a second thought is that Eastern and NGN both have big stakes in this (not big for them) and so I would expect that what is happening must have excellent value for them.

I sure welcome the liquidity if it comes to an IPO.

I'll go back to the SEDARs but if anybody can give insight as to who has the preferred shares it would be much appreciated.

Regards

Toinv